Get the Stockscreener App
87.93
0.37%
0.68
Axsome Therapeutics Inc stock is traded at $87.93, with a volume of 105.77K.
It is up +0.37% in the last 24 hours and up +1.14% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$87.25
Open:
$86.84
24h Volume:
105.77K
Relative Volume:
0.26
Market Cap:
$4.14B
Revenue:
$291.49M
Net Income/Loss:
$-308.55M
P/E Ratio:
-19.41
EPS:
-4.53
Net Cash Flow:
$-168.02M
1W Performance:
-3.07%
1M Performance:
+1.14%
6M Performance:
+17.08%
1Y Performance:
+34.44%
1-Day Range:
$86.06
$87.90
1-Week Range:
$86.06
$91.10
52-Week Range:
$55.02
$98.40
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Sells 29,486 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
(AXSM) Trading Advice - Stock Traders Daily
Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR
Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Major Depressive Disorder Market Expected to Experience Major - openPR
Axsome Therapeutics Presents Data from Multiple Programs - GlobeNewswire
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - Yahoo Finance
Axsome to Showcase Solriamfetol Research on Daytime Sleepiness and Cognition in OSA and Narcolepsy - Sleep Review
Values First Advisors Inc. Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Hennion & Walsh Asset Management Inc. Has $5.23 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Zacks Research Brokers Reduce Earnings Estimates for AXSM - MarketBeat
Learn to Evaluate (AXSM) using the Charts - Stock Traders Daily
3 Bargain Stocks to Buy in a Market That's Priced for Perfection - sharewise
3 Bargain Stocks to Buy in a Market That's Priced for Perfection - The Motley Fool
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Axsome: AXS-07 And Its Upcoming Second PDUFA (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 - The Manila Times
AQR Capital Management LLC Sells 15,440 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition? - Yahoo Finance
SG Americas Securities LLC Makes New $1.04 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
(AXSM) Technical Pivots with Risk Controls - Stock Traders Daily
Mizuho maintains Outperform rating on Axsome Therapeutics shares - Investing.com
Mizuho maintains Outperform rating on Axsome Therapeutics shares By Investing.com - Investing.com Australia
Bank of Montreal Can Takes $849,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives $124.64 Average Target Price from Analysts - MarketBeat
Clearbridge Investments LLC Raises Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 3.1%Should You Sell? - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given New $131.00 Price Target at Royal Bank of Canada - MarketBeat
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit - Simply Wall St
Axsome Therapeutics (NASDAQ:AXSM) Trading 4.9% Higher - MarketBeat
Axsome Therapeutics amends loan agreement, expands covenants By Investing.com - Investing.com Australia
Axsome Therapeutics amends loan agreement, expands covenants - Investing.com India
Millennium Management LLC Grows Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome to Present Data on AXS-12 and Solriamfetol at Sleep Europe 2024 - Sleep Review
Perceptive Advisors LLC Trims Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
FDA Accepts AXSM's NDA Resubmission for Migraine Drug, Stock Up - MSN
1 Under-the-Radar Biotech Stock to Buy and Hold - sharewise
When (AXSM) Moves Investors should Listen - Stock Traders Daily
Wall Street SWOT: Axsome stock fortified by robust IP and CNS market potential - Investing.com
Ford Motor Company (F-N) QuotePress Release - The Globe and Mail
Point72 Europe London LLP Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Affinity Asset Advisors LLC - MarketBeat
AxoGen (NASDAQ:AXGN) Upgraded by StockNews.com to Buy - Defense World
Upward Trajectory: Aquestive Therapeutics Inc (AQST) Posts a Slidee, Closing at 4.88 - The Dwinnex
First Light Asset Management LLC Purchases 2,578,147 Shares of AxoGen, Inc. (NASDAQ:AXGN) - MarketBeat
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Axsome Therapeutics Inc Stock (AXSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):